安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Mepolizumab: Uses, Dosage, Side Effects, Warnings - Drugs. com
Mepolizumab is used to treat several eosinophil-related conditions including Hypereosinophilic Syndrome (HES), Eosinophilic Granulomatosis with Polyangiitis (EGPA), severe asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP)
- Discover a COPD Treatment Option | NUCALA (mepolizumab)
NUCALA (mepolizumab) is now approved as an add-on, prescription maintenance treatment for adults with uncontrolled eosinophilic COPD Not for sudden breathing problems
- Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic . . .
Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with
- Mepolizumab (subcutaneous route) - Mayo Clinic
Mepolizumab injection is used with other medicines to treat severe asthma It is given to patients whose asthma is not controlled with their current asthma medicines It is also used to treat eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES)
- Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA . . .
Mepolizumab is a humanized, IL-5 antagonist monoclonal antibody (immunoglobulin G1 kappa) 8 The IL-5 cytokine regulates the growth, recruitment, activation, and life cycle of eosinophils—one of several cell types involved in asthma-related airway inflammation 8
- Mepolizumab Injection: MedlinePlus Drug Information
Mepolizumab injection is used along with other medications to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in certain children 6 years of age and older and adults whose asthma is not controlled with their current asthma medication (s)
- label - Food and Drug Administration
NUCALA (mepolizumab) injection, for subcutaneous use • Injection: 100 mg mL, single-dose, prefilled autoinjector or single-dose Initial U S Approval: 2015
- INTRODUCTION - Mepolizumab (Nucala) - NCBI Bookshelf
Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine responsible for regulating eosinophil maturation, differentiation, recruitment, activation, and survival
|
|
|